In Part 6 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho and Diabetes in Control publisher Steve Freed discuss the possible reduction in the use of insulin as well as hypoglycemia following the use of the product.
Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc. In his role at Diasome, he leads the management and strategic direction of the Company’s targeted insulin therapies, novel type 2 diabetes technology, and oral therapy for obesity.
If you prefer to view the entire video, click here.
A full transcript of the entire video is available here.
To view other segments in this video:
Part 1: Diasome Pharmaceuticals Drug Delivery System
Part 2: Does insulin cause the liver to stop producing glucagon?
Part 3: Are your starting early Phase 3 trials?
Part 4: What are the benefits of a mixed insulin?
Part 5: How will this affect weight?
Part 6: How much have you seen in the reduction of insulin use?
Part 7: How are you going to market this?